---
schema_version: "secwatch.filing_event.v1"
accession: "0001933414-24-000006"
form_type: "8-K"
ticker: "MLYS"
cik: "0001933414"
company_name: "Mineralys Therapeutics, Inc."
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:56:04.489856+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mineralys Therapeutics raises $120M in private placement; funds lorundrostat development

## Summary
- PIPE of ~8.9M shares/pre-funded warrants at $13.50/share; gross proceeds ~$120M.
- Lead investors TCGX and RA Capital Management, joined by OrbiMed, Venrock, Samsara, and others.
- Net proceeds to fund R&D of lorundrostat (aldosterone-driven hypertension/CKD) and general corporate purposes.
- PIPE expected to close Feb 12, 2024; BofA Securities and Evercore as placement agents.
- Registration statement to be filed within 60 days of closing for resale of shares and warrant shares.

## SEC filing metadata
- accession: 0001933414-24-000006
- form_type: 8-K
- ticker: MLYS
- cik: 0001933414
- company_name: Mineralys Therapeutics, Inc.
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000006/0001933414-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000006/mlys-20240207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001933414-24-000006
- JSON: https://secwatch.observer/filing/0001933414-24-000006.json
- Plain text: https://secwatch.observer/filing/0001933414-24-000006.txt

## Key facts
- Material Agreements
  Mineralys Therapeutics, Inc. entered into Purchase Agreement with purchasers named therein valued at approximately $120 million (effective 2024-02-07).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: purchasers named therein
  - Value: approximately $120 million
  - Effective: 2024-02-07
  source text: On February 7, 2024, Mineralys Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 8,339,169 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price of $13.50 per Share, and (ii) with respect to certain Purchasers, pre-funded warrants to purchase an aggregate of 549,755 shares of Common Stock (the “Pre-Funded Warrants”) in lieu of shares of Common Stock, at a purchase price of $13.499 per Pre-Funded Warrant (the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants, the “Warrant Shares”). The aggregate gross proceeds for the Private Placement are expected to be approximately $120 million, before deducting offering expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1933414/000193341424000006/0001933414-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.